This is a prospective, observational study to collect stool and blood from acute myeloid leukemia patients undergoing intensive chemotherapy.
Study Type
OBSERVATIONAL
Enrollment
54
Collected from each patient twice weekly.
Collected from each patient twice weekly.
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Abundance of Phyla
Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform
Time frame: Day 28
Abundance of Genera
Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform
Time frame: Day 28
Circulating Microbiota Diversity (Blood)
Describe circulating microbiota diversity over the course of treatment
Time frame: Day 28
Microbiota Diversity (Stool)
Describe stool microbiota diversity over the course of treatment
Time frame: Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.